↓ Skip to main content

Biomarkers in acute myocardial infarction

Overview of attention for article published in BMC Medicine, June 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
facebook
2 Facebook pages

Citations

dimensions_citation
199 Dimensions

Readers on

mendeley
460 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Biomarkers in acute myocardial infarction
Published in
BMC Medicine, June 2010
DOI 10.1186/1741-7015-8-34
Pubmed ID
Authors

Daniel Chan, Leong L Ng

Abstract

Myocardial infarction causes significant mortality and morbidity. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction or acute coronary syndrome. This may facilitate tailoring of appropriate therapy to high-risk patients. This review focuses on a variety of promising biomarkers which provide diagnostic and prognostic information. Heart-type Fatty Acid Binding Protein and copeptin in combination with cardiac troponin help diagnose myocardial infarction or acute coronary syndrome in the early hours following symptoms. An elevated N-Terminal Pro-B-type Natriuretic Peptide has been well validated to predict death and heart failure following a myocardial infarction. Similarly other biomarkers such as Mid-regional pro-Atrial Natriuretic Peptide, ST2, C-Terminal pro-endothelin 1, Mid-regional pro-Adrenomedullin and copeptin all provide incremental information in predicting death and heart failure. Growth differentiation factor-15 and high-sensitivity C-reactive protein predict death following an acute coronary syndrome. Pregnancy associated plasma protein A levels following chest pain predicts risk of myocardial infarction and revascularisation. Some biomarkers such as myeloperoxidase and high-sensitivity C-reactive protein in an apparently healthy population predicts risk of coronary disease and allows clinicians to initiate early preventative treatment. In addition to biomarkers, various well-validated scoring systems based on clinical characteristics are available to help clinicians predict mortality risk, such as the Thrombolysis In Myocardial Infarction score and Global Registry of Acute Coronary Events score. A multimarker approach incorporating biomarkers and clinical scores will increase the prognostic accuracy. However, it is important to note that only troponin has been used to direct therapeutic intervention and none of the new prognostic biomarkers have been tested and proven to alter outcome of therapeutic intervention. Novel biomarkers have improved prediction of outcome in acute myocardial infarction, but none have been demonstrated to alter the outcome of a particular therapy or management strategy. Randomised trials are urgently needed to address this translational gap before the use of novel biomarkers becomes common practice to facilitate tailored treatment following an acute coronary event.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 460 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 <1%
Brazil 3 <1%
Turkey 2 <1%
Sweden 2 <1%
Chile 1 <1%
Germany 1 <1%
Iran, Islamic Republic of 1 <1%
France 1 <1%
Spain 1 <1%
Other 3 <1%
Unknown 441 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 71 15%
Student > Ph. D. Student 67 15%
Student > Master 56 12%
Researcher 49 11%
Student > Postgraduate 35 8%
Other 101 22%
Unknown 81 18%
Readers by discipline Count As %
Medicine and Dentistry 194 42%
Agricultural and Biological Sciences 53 12%
Biochemistry, Genetics and Molecular Biology 36 8%
Chemistry 15 3%
Nursing and Health Professions 14 3%
Other 53 12%
Unknown 95 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2023.
All research outputs
#2,444,740
of 24,496,759 outputs
Outputs from BMC Medicine
#1,609
of 3,782 outputs
Outputs of similar age
#8,836
of 100,549 outputs
Outputs of similar age from BMC Medicine
#7
of 16 outputs
Altmetric has tracked 24,496,759 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,782 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.1. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 100,549 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.